Gonadorelin Research, Specifications & Scientific Information

Introduction

Gonadorelin is not an analogue of gonadotropin-releasing hormone. It is gonadotropin-releasing hormone — the ten-residue hypothalamic peptide whose sequence was determined from porcine hypothalamic extract in 1971, work that anchored one end of the reproductive axis and later carried a Nobel Prize ^[1].

That makes this entry unusual in a library mostly concerned with designed molecules. There is nothing to explain about why a chemist made a substitution, because nobody did. What there is to explain is a single experimental finding, published in Science in 1978, that governs everything done with this hormone and with every analogue of it since: the pituitary responds to how the signal arrives, not only to how much of it there is. Delivered in pulses, the hormone sustains gonadotropin secretion. Delivered continuously, it shuts it down ^[2].

Two opposite branches of clinical practice grew from that one result — pump-delivered pulsatile therapy to switch the axis on, and long-acting agonists such as triptorelin to switch it off. Both are described below.

What Is Gonadorelin?

Gonadorelin is the International Nonproprietary Name for the native decapeptide pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, also written GnRH and, in older literature, LHRH. PubChem carries it under compound identifier 638793, with CAS registry number 33515-09-2 and FDA/NCATS UNII code 9O7312W37G.

It is produced by hypothalamic neurons and released into the hypophyseal portal circulation, where it reaches the anterior pituitary. Its half-life in plasma is a few minutes — appropriate for a signalling molecule whose whole function is to deliver discrete pulses, and awkward for anyone wanting to use it as a medicine, which is why the analogues exist.

Its regulatory position is genuinely several positions at once, and the WHO classification reflects that: it holds an ATC code in the systemic hormone class, another in the diagnostic-agent class, and a veterinary ATC code. In practice that corresponds to three distinct uses — a pituitary function test, a pulsatile therapy in specialist endocrinology, and a component of cattle reproduction protocols. Finished products have been approved in the United States for human diagnostic assessment of gonadotrope function and for pulsatile administration in primary hypothalamic amenorrhoea, and availability of those human products has changed over time. Veterinary products containing the substance are approved for cattle.

Every one of those approvals attaches to a specific finished product and indication. None of them extends to research-grade material supplied for laboratory use.

Gonadorelin Specifications

Gonadorelin is the natural hypothalamic decapeptide itself, not an analogue of it: the sequence determined from porcine hypothalamic extract in 1971 is the sequence of the molecule sold under this International Nonproprietary Name. Both termini are modified in the natural molecule — the N-terminal glutamine is cyclised to pyroglutamate and the C-terminal glycine is amidated — and both modifications are required for activity rather than being stabilising additions. PubChem carries the peptide under compound identifier 638793, with CAS registry number 33515-09-2 and the FDA/NCATS UNII code 9O7312W37G; an acetate salt form has its own UNII, 2RG1XQ1NYJ, and material supplied as a reagent is commonly an acetate whose mass differs from the free-peptide figure. The substance holds WHO ATC codes in both the human systemic hormone class and the diagnostic-agent class, and a veterinary ATC code, which reflects the three quite different contexts in which it is used.

Values that a public register does not carry are shown as not publicly characterised rather than estimated. Identifiers are reference values; the certificate of analysis supplied with a laboratory order is the record for a given lot.

How Does Gonadorelin Work?

The receptor is the gonadotropin-releasing hormone receptor, a Gq/11-coupled class A G protein-coupled receptor on pituitary gonadotrope cells. Binding stimulates release of luteinising hormone and follicle-stimulating hormone, which act on the gonads to drive gametogenesis and sex steroid production.

Stated that way it sounds like ordinary agonist pharmacology, and it is not. The distinguishing feature of this receptor is the consequence of sustained occupancy.

In 1978 a study delivered the hormone to primates in two different patterns — continuously, and intermittently — while measuring pituitary output. The intermittent pattern sustained gonadotropin secretion. The continuous pattern produced the opposite: the pituitary desensitised, and gonadotropin secretion fell ^[2]. Same molecule, same receptor, same total exposure; opposite physiological result, determined by timing alone.

Three things follow, and between them they account for most of the clinical pharmacology in this area.

Therapy with the native hormone requires a pump. A hormone with a several-minute half-life that must arrive in pulses cannot be given as a simple injection schedule. Pulsatile GnRH therapy uses a portable pump delivering small amounts every sixty to ninety minutes.

Long-acting analogues suppress rather than stimulate. An analogue engineered for a long half-life necessarily produces continuous receptor occupancy, which by the 1978 result means desensitisation. That is why triptorelin and its relatives are used to shut the axis down in prostate cancer and in precocious puberty — the suppression is the intended effect, arrived at through an agonist.

The diagnostic use exploits the acute response. Before desensitisation sets in, a single administration produces a measurable gonadotropin rise, and the size and shape of that rise reports on the functional capacity of the gonadotropes. That is what the diagnostic products were approved for.

Gonadorelin Mechanism of Action

The mechanism above rests on classical endocrine physiology rather than on modern in vitro receptor work performed on this specific preparation, and no cell-culture characterisation of gonadorelin was located for this page. The two load-bearing results are the 1971 structure determination ^[1] and the 1978 pattern-dependence experiment ^[2], and both are cited above where they are used.

What should not be inferred is that the mechanism is uncertain. It is among the best-established in endocrinology — the reason there is no long list of mechanistic citations here is that the question was settled fifty years ago, not that it is open.

What Is Gonadorelin Being Researched For?

• Fertility induction in congenital hypogonadotropic hypogonadism — pulsatile administration compared against combined gonadotropin therapy for inducing spermatogenesis ^[3], within a wider landscape of fertility-induction strategies for that condition ^[4].
• Pituitary gonadotrope function testing — the diagnostic application, which exploits the acute gonadotropin response before desensitisation.
• Bovine reproductive synchronisation — where it is a standard component of timed-insemination protocols, and where research continues on how much to give and when ^[5].

Each of those is research on an approved product or on a clinical protocol, conducted in patients or in livestock. None of it is research into, or evidence about, research-grade material supplied for laboratory use.

Human Research on Gonadorelin

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

Pulsatile administration for spermatogenesis in congenital hypogonadotropic hypogonadism, 2025

Setting. Congenital hypogonadotropic hypogonadism is a rare condition in which the hypothalamic GnRH signal is absent or inadequate. Two strategies can restore fertility: replacing the downstream gonadotropins directly, or replacing the upstream pulsatile signal and letting the pituitary produce its own.

Design and result as reported. A 2025 study compared outcomes between pulsatile GnRH therapy and combined gonadotropin therapy for spermatogenesis in patients with the condition ^[3]. It is a comparison of two established approaches in a rare disease, not a placebo-controlled trial, and its value lies in that comparison.

Context. A 2024 review sets out the wider landscape of fertility induction in males with the condition, within which both strategies sit ^[4].

Limitations. Rare-disease endocrinology is conducted in small cohorts at specialist centres, frequently without randomisation, and the choice between strategies is influenced by cost, pump tolerance and local practice as well as by biology. Conclusions from such comparisons are real but are not of the same kind as those from a large randomised trial.

The pattern-dependence result, and why it is on this page

Design and result as reported. Continuous and intermittent delivery of the hormone were compared for their effect on pituitary output. The two patterns produced opposite outcomes: intermittent delivery sustained gonadotropin secretion, continuous delivery suppressed it ^[2].

Why it belongs in the human section even though the experiment was not in humans. It is the result that determines how the hormone is given to people, what a long-acting analogue does to a patient, and why one class of compound stimulates the reproductive axis while a chemically similar class suppresses it. No fact about this molecule is more consequential in clinical practice.

Preclinical Research on Gonadorelin

Animal research

Animal work with this hormone is unusual in that a substantial part of it is not a model of human physiology at all — it is agricultural practice in its own right.

Cattle reproduction. Products containing gonadorelin hydrochloride are standard components of timed artificial insemination protocols in dairy and beef cattle. A 2026 study in the Journal of Dairy Science examined the effect of increasing the amount given at the first injection of a breeding protocol, reporting on luteinising hormone release, ovulatory response and pregnancy at first service in lactating dairy cows ^[5].

What this evidence is for. It is research in cattle, conducted to improve herd fertility management, and it is included here because veterinary approvals are a real part of this substance's regulatory position. Findings described in this section were observed in cattle and in non-human primates. Nothing in them establishes anything about humans.

Current Research Status

Status as of September 22, 2026. This block is rendered from maintained fields, not from prose, so it cannot go stale in one place and stay current in another.

Gonadorelin vs Related Compounds

Against Triptorelin and the long-acting agonists

Triptorelin differs from this molecule by a single substituted residue and by its formulation for sustained release. Because sustained receptor occupancy desensitises the gonadotropes ^[2], the analogue suppresses the axis where the native hormone in pulses stimulates it. Two closely related molecules with opposite clinical purposes is an unusually clean illustration of pharmacology depending on exposure pattern rather than on structure alone.

Against the kisspeptins

Kisspeptin-54 and kisspeptin-10 act one level further up, on the hypothalamic neurons that release this hormone, rather than on the pituitary. A kisspeptin stimulus reaches the pituitary as endogenous GnRH with the hypothalamus's own timing; this hormone reaches it directly, with whatever timing the delivery device imposes.

Against GnRH antagonists

Antagonists such as cetrorelix block the receptor immediately without the initial stimulation that an agonist produces. Where an agonist suppresses the axis only after a period of stimulation and desensitisation, an antagonist suppresses it at once. The distinction matters clinically and is a property of the molecular class, not of any amount given.

Its own position

This is the reference molecule of the family — the natural ligand against which every analogue is defined, and the only member of it that is the hormone rather than a version of it.

No comparison of effect between these compounds is made on this page.

Chemical & Molecular Characteristics

Gonadorelin is a ten-residue peptide of molecular formula C55H75N17O13 and average mass 1182.3 g/mol, recorded under PubChem compound identifier 638793 and CAS registry number 33515-09-2.

Both terminal modifications are part of the natural molecule. The N-terminal residue is pyroglutamate, a cyclised glutamine, and the C-terminus is an amide. In most peptides in this library, modifications of this kind are introduced deliberately to improve stability. Here they are what the body makes, they were part of the structure determined in 1971 ^[1], and both are required for receptor activation. A preparation carrying a free N-terminal glutamine or a free C-terminal acid is not this hormone.

Those same modifications are analytically awkward in opposite directions. Pyroglutamate formation is a common spontaneous change in peptides that begin with glutamine, so it can be an impurity elsewhere and is the correct structure here — meaning the usual diagnostic logic is reversed. C-terminal amidation, by contrast, is one dalton away from the free acid, a difference at the resolution limit of routine mass spectrometry on a 1.2 kDa peptide. Neither terminus can be confirmed casually.

Tryptophan and tyrosine give it a chromophore and a liability. The single tryptophan at position 3 and the tyrosine at position 5 make the peptide straightforward to quantify at 280 nm. Tryptophan is also the residue most prone to oxidation and photodegradation, and its oxidation products are close in mass and often incompletely resolved from the parent.

The half-life is a property of the molecule, not of the formulation. A plasma half-life of a few minutes is intrinsic to an unprotected decapeptide with exposed cleavage sites. Every long-acting compound in this family exists because that half-life could not be engineered away without changing the sequence.

Salt form. An acetate salt has its own UNII, 2RG1XQ1NYJ, and reagent material is commonly an acetate. A mass or purity figure that does not state the counter-ion and water content is incomplete.

Frequently Asked Questions

Scientific References

1. Matsuo H, Baba Y, Nair RM, et al.. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence Biochemical and biophysical research communications; 1971. PMID 4936338 doi:10.1016/s0006-291x(71)80019-0
2. Belchetz PE, Plant TM, Nakai Y, et al.. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone Science (New York, N.Y.); 1978. PMID 100883 doi:10.1126/science.100883
3. Zheng Y, Bai HZ, Zhao GC, et al.. Comparison of outcomes between pulsatile gonadotropin releasing hormone and combined gonadotropin therapy of spermatogenesis in patients with congenital hypogonadotropic hypogonadism Reproductive biology and endocrinology : RB&E; 2025. PMID 40119359 doi:10.1186/s12958-025-01370-7
4. Dwyer AA, McDonald IR, Quinton R. Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism Annals of the New York Academy of Sciences; 2024. PMID 39190467 doi:10.1111/nyas.15214
5. Lima FS, Bruno RGS, Cleale RM, et al.. Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone release, ovulatory response, and pregnancy in first-service lactating dairy cows Journal of dairy science; 2026. PMID 41698585 doi:10.3168/jds.2025-27334

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.